Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.

[1]  Y. Matsui,et al.  Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II–Induced Cardiac Hypertrophy , 2004, Hypertension.

[2]  H. Okamoto.  Osteopontin and cardiovascular system , 2007, Molecular and Cellular Biochemistry.

[3]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[4]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[5]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[6]  H. Mabuchi,et al.  Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[7]  W A Hsueh,et al.  Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. , 1996, The Journal of clinical investigation.

[8]  R Hetzer,et al.  Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. , 1997, Circulation.

[9]  G. Lip,et al.  History and epidemiology , 2000, BMJ : British Medical Journal.

[10]  R. Körfer,et al.  The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  Hendrik Milting,et al.  CardioWest total artificial heart: Bad Oeynhausen experience. , 2005, The Annals of thoracic surgery.

[12]  R. Hetzer,et al.  Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. , 2001, Journal of the American College of Cardiology.

[13]  M. Hiroe,et al.  Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. , 2004, Histology and histopathology.

[14]  T. Ueda,et al.  Circulating matrix metalloproteinase‐2 is elevated in patients with congestive heart failure , 2003, European journal of heart failure.

[15]  A. Feldman,et al.  Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.

[16]  N. Ozer,et al.  Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. , 2006, The American journal of cardiology.

[17]  C. H. Conrad,et al.  Myocardial osteopontin expression coincides with the development of heart failure. , 1999, Hypertension.

[18]  J. Park,et al.  Expression and immunohistochemical localization of galectin‐3 in various mouse tissues , 2007, Cell biology international.

[19]  Magdi H Yacoub,et al.  Left ventricular assist device and drug therapy for the reversal of heart failure. , 2006, The New England journal of medicine.

[20]  C. Kielty,et al.  The Collagen Family: Structure, Assembly, and Organization in the Extracellular Matrix , 2003 .

[21]  P. Carmeliet,et al.  Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart , 2005, Circulation.

[22]  G. Lip,et al.  ABC of heart failure. , 2000, BMJ.

[23]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[24]  Alan S Maisel,et al.  Cardiac biomarkers: a contemporary status report , 2006, Nature Clinical Practice Cardiovascular Medicine.

[25]  G. Keren,et al.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. , 2005, American heart journal.

[26]  P. Ellinor,et al.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.

[27]  M. Hiroe,et al.  Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. , 2005, The American journal of pathology.

[28]  M. Hiroe,et al.  Diagnostic utility of tenascin‐C for evaluation of the activity of human acute myocarditis , 2005, The Journal of pathology.

[29]  R. Körfer,et al.  The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  J. Schaper,et al.  Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. , 2004, Journal of the American College of Cardiology.

[31]  D. Gardner,et al.  Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. , 1999, The Journal of clinical investigation.

[32]  A. Sato,et al.  Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[33]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[34]  R. Körfer,et al.  Influence of ACE‐inhibition and mechanical unloading on the regulation of extracellular matrix proteins in the myocardium of heart transplantation candidates bridged by ventricular assist devices , 2006, European journal of heart failure.

[35]  Zhonglin Xie,et al.  Osteopontin Inhibits Interleukin-1β-stimulated Increases in Matrix Metalloproteinase Activity in Adult Rat Cardiac Fibroblasts , 2002, Journal of Biological Chemistry.

[36]  Magdi H Yacoub,et al.  A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  Leslie L. Clark,et al.  Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.

[38]  David R. Buvat de Virginy.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure , 2006, Heart Failure Reviews.